From the Research
Wellbutrin (bupropion) should be used with caution in patients with stable atrial flutter, and consultation with a cardiologist is strongly recommended before starting this medication. According to the most recent and highest quality study available, 1, which is a network meta-analysis published in 2024, the primary concern with using Wellbutrin in patients with atrial flutter is its potential to worsen cardiac arrhythmias. The medication can affect heart rate and rhythm by stimulating the cardiovascular system through its norepinephrine effects.
Some key points to consider when using Wellbutrin in patients with stable atrial flutter include:
- Starting at a low dose (such as 100mg once daily) with gradual titration and regular cardiac monitoring would be prudent.
- The extended-release formulation (Wellbutrin XL) may provide more stable blood levels and potentially less cardiac impact than immediate-release versions.
- Patients should immediately report any symptoms of palpitations, dizziness, or chest discomfort while taking this medication, as these could indicate worsening of the cardiac condition.
- Alternative antidepressants like SSRIs (such as sertraline or citalopram) may be safer options for patients with stable atrial flutter who require treatment for depression or smoking cessation.
It's also important to note that the management of atrial flutter involves rate control, rhythm control, and anticoagulation therapy, as discussed in 2 and 3. However, the use of Wellbutrin in patients with atrial flutter is not directly addressed in these studies. The study 1 provides the most relevant and up-to-date information on the management of atrial fibrillation and atrial flutter, and its findings should be taken into consideration when making treatment decisions for patients with these conditions.